NASDAQ
8.10USD
+0.22 (+2.79%)
We have scored 9 news catalysts on Greenland Mines Ltd. (GRML) over the past 12 months. The biggest single-day move next to one of them came Sep 21, 2026, when GRML closed +230.5%: “GameStop CEO Ryan Cohen Buys Another $26 Million of GME Stock”. Coverage across the window leans positive (average ticker sentiment +0.71). Most of the impact sits in price momentum and input specificity.
Dots are scored news catalysts — size = impact, color = sentiment. Tap one to read it.
Market cap
23.4M
P/E
—
EPS
—
Beta
2.48
52W range
0.1578-18.08
Day range
8.00–8.65
Open
8.65
Prev close
7.88
Volume
1.9M
Avg volume
4.9M
Dividend
0.00
IPO
2022-04-29
Daily OHLCV with SMA overlays and session pivots. Draw your levels and trendlines on it, or ask the AI analyst what the price is reacting to.
Suppliers, customers, partners and competitors, derived from what the news actually says about Greenland Mines Ltd. — not a sector bucket. Click an edge to see the articles that established the link.
Latest scored catalyst for GRML: .
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Greenland Mines Ltd operates across two segments: natural resources and cell and gene therapy. Its resources arm is focused on exploring for palladium, gold, and platinum, centered on the exploration and development of the Skaergaard project in Southeast Greenland. On the therapeutics side, the company is developing KLTO-202, a gene therapy targeting the treatment and prevention of amyotrophic lateral sclerosis (ALS), and KLTO-101, aimed at treating or preventing Alzheimer's disease, alongside therapies for Parkinson's and other age-related conditions. Previously known as Klotho Neurosciences, Inc., the company adopted its current name in March 2026. It is headquartered in Charlotte, North Carolina.
